Peptide Based Gastrointestinal Disorders Therapeutics Market Size, Trends, Share and Growth Forecast till 2022

Recently, a novel report developed using proven research methodologies at the headquarters of Fact. MR has identified various prominent factors and trends prompting market growth of peptide based gastrointestinal disorders therapeutics market. The study is titled as “Peptide Based Gastrointestinal Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022”, which deeply analyses the global market trends, with historical data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) during the mentioned forecast of 2017-2022. For the benefit of the readers, the report concludes with a special focus on the detailed profiles of the major vendors in the global peptide based gastrointestinal disorders therapeutics market.

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=190

Pharmaceutical companies are increasingly collaborating with medical institutes and research centers in order to ramp up R&D pipelines of peptide drugs. This is expected to influence the growth of the global peptide based gastrointestinal disorders therapeutics market over the next couple of years. Rising prevalence of metabolic diseases and gastrointestinal disorders pertaining to the digestive system is prompting medical practitioners to utilize new therapeutics including peptides. In the near future, application of peptides is also expected to increase in other therapeutic areas as well. Moreover, technological advancement in peptide synthesis which include hybrid combination of liquid and solid synthesis and high-throughput approaches is expected to play a crucial role in development of more effective peptide based therapeutic drugs for treating gastrointestinal disorders. Such developments in the peptide therapeutics is also giving new hope to patients seeking affordable and effect therapeutic treatments. In addition, manufacturers are actively focusing on improving peptide properties, such as half-life and stability to address the various unmet medical needs. According to the latest report published by Fact.MR, the global peptide based gastrointestinal disorders therapeutics market is set to reflect a double-digit CAGR between 2017 and 2022, to surpass a valuation of US$ 600 Mn.

Highlights of the Report Include:

North America currently commands for the largest share of the global market in terms of revenue and the trend is likely to continue over the next five years. The region’s market is expected to expand at little under 14% CAGR over the forecast period. This growth is attributed to the rising adoption of peptide based drugs and increasing patient awareness about new and novel therapeutic treatments.

Browse Full Report with TOC- https://www.factmr.com/report/190/peptide-based-gastrointestinal-disorders-therapeutics-market

Based on drugs, global sales of linaclotide for treatment of gastrointestinal ailments is significantly high. Sales of linaclotide currently commands for over two-third revenue share of the global market. By the end of 2022, over US$ 466 Mn worth linaclotide peptide drugs are estimated to be sold across the globe.

Hospital pharmacies is expected to remain the most attractive distribution channel for peptide based gastrointestinal disorders therapeutic drugs throughout the assessment period. In terms of revenue, hospital pharmacies currently account for nearly 50% share of the global market and the figure is unlikely observer any major alteration over 2022. Meanwhile, retail pharmacies will continue to hold the second position and reflect an impressive growth during the five years of forecast.

North America to Lead the Global Peptide Based Gastrointestinal Disorders Therapeutics Market

In terms of revenue, North America is expected to hold the dominant share of the global peptide based gastrointestinal disorders therapeutics market in 2017 and beyond. Factors such growing patient awareness and rapid adoption of peptide based therapeutics for treating various diseases are expected to support the growth of the market in the region. During the forecast period, the market in the region is projected to surge at a robust CAGR of 13.9%.

On the basis of drugs, the linaclotide segment is expected to retain its dominant position over 2022. Currently, the segment accounts for more than two-third share of the market in terms of revenue. Towards the end of the forecast period, the linaclotide segment is estimated to reach a market valuation in excess of US$ 466 Mn.

Table of Contents:

1. Global Peptide Based Gastrointestinal Disorders Therapeutics Market – Executive Summary

2. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Overview
2.1. Introduction
2.1.1. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Taxonomy
2.1.2. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Definition
2.2. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
2.2.1. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Dynamics
2.4. Regulations

3. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Analysis and Forecast By Drug
3.1. Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size and Forecast By Drug, 2012-2022
3.1.1. Teduglutide Peptide Based Gastrointestinal Disorders Therapeutics Market Size and Forecast, 2012-2022
3.1.1.1. Revenue (US$ Mn) Comparison, By Region
3.1.1.2. Market Share Comparison, By Region
3.1.1.3. Y-o-Y growth Comparison, By Region
Continued……….

Request Methodology of the Report- https://www.factmr.com/connectus/sample?flag=RM&rep_id=190

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593
Email: sales@factmr.com
Web: https://www.factmr.com/
Follow us in Linkedin: https://www.linkedin.com/company/factmr/

This release was published on openPR.